|
    MRNA U.S.: Nasdaq

    Moderna Inc.

    MRNAUS
    After Hours
    Back To Top
    Last Updated: Apr 28, 2020 7:59 p.m. EDT Delayed quote

    $ 48.35

    0.47 0.98%
    After Hours Volume: 328.2K
    Health Care/Life Sciences 1.59%
    Close Chg Chg %
    $47.88 -0.17 -0.35% -0.17 -0.35%
    Advanced Charting
    • $
    • %
    • Vol
    Advanced Charting
    81.60% vs Avg.
    Volume: 13.1M 65 Day Avg. - 16M
    Open: 50.40
    Close: 47.88
    47.17 Day Low/High 50.45
    Day Range
    11.54 52 Week Low/High 56.38

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    Key Data

    • Open $50.40
    • Day Range 47.17 - 50.45
    • 52 Week Range 11.54 - 56.38
    • Market Cap $15.81B
    • Shares Outstanding 329M
    • Public Float 199.51M
    • Beta 0.15
    • Rev. per Employee $177.72K
    • P/E Ratio n/a
    • EPS $-1.56
    • Yield n/a
    • Dividend n/a
    • Ex-Dividend Date n/a
    • Short Interest 23.88M 04/15/20
    • % of Float Shorted 11.97%
    • Average Volume 16.01M

    Performance

    5 Day
    • -2.80%
    1 Month
    • 59.87%
    3 Month
    • 114.13%
    YTD
    • 144.79%
    1 Year
    • 83.94%

    Recent News

    • MarketWatch
    • WSJ
    Read full story

    Coronavirus update: German infection rate ticks higher after reopening moves, offers lesson to U.S. governors

    Good News on Oxford Covid-19 Vaccine Offers Hope

    A vaccine developed by academic scientists at the University of Oxford is moving quickly into large clinical trials, giving investors a dose of optimism.

    Read full story

    How to develop and distribute a COVID-19 vaccine for all

    Moderna's coronavirus vaccine candidate advances to next stage of testing

    Moderna Inc. said late Monday its candidate for a coronavirus vaccine will get to be evaluated further. The biotech company said it has submitted a new-drug application with the U.S. Food and Drug Administration to evaluate the vaccine candidate, mRNA-1273, in a more extensive study if supported by safety data from an initial study. The phase 2 study is expected to begin in the second quarter, Moderna said. That will evaluate the safety and any adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart, the company said. Each person participating in the study will be assigned to receive a placebo or different doses of the vaccine candidate, Moderna said. The plan is to enroll 600 healthy adults and older adults in two cohorts, Participants will be followed through 12 months after the second vaccination, Moderna said. "Submitting this (investigative new-drug application) is an important next step in the clinical development of our mRNA vaccine against SARS-CoV-2, and we are moving rapidly to potentially address this global health emergency," Moderna's Chief Medical Officer Tal Zaks said in a statement. A third phase could begin in the fall of 2020, the company said. Moderna is one ofnearly two dozen U.S. companies working on a vaccine against COVID-19 as the disease has killed more than 200,000 worldwide.

    Read full story

    Harvard prof rides 17,000% return in a single stock to become a billionaire

    Biotech and Pharmaceutical Stocks Beat the Market in Recessions

    On a relative basis, biotech and pharmaceutical indexes outperformed the S&P 500 by 18% and 10%, respectively, in the past three recessions, according to SVB Leerink analyst Geoffrey Porges.

    Read full story

    This battle-tested pro in the stock market explains how you can ‘come out swinging’ when the pandemic eases

    A Covid-19 Vaccine Could Take Longer Than Investors Expect

    Companies like Moderna, J&J, Glaxo, and Sanofi are making a big push to find a vaccine. But some experts say it may take until 2022 or 2023 before one is available for billions of people.

    Read full story

    Coronavirus update: 2.2 million cases worldwide, 150,948 deaths; China revises Wuhan death toll 50% upward

    Moderna Gets U.S. Government Grant to Develop Covid-19 Vaccine

    Its stock jumped after the biotech said it would receive nearly half a billion dollars from an arm of the federal government.

    Stock Futures Soar on Report of Covid-19 Patients Responding to Gilead Drug

    Of 125 patients taking Gilead’s drug remdesivir, most have been discharged, according to a report.

    Moderna coronavirus vaccine effort to get $483 million in federal funding

    Moderna Inc. said late Thursday that it will receive up to $483 million from the U.S. government to accelerate development of a COVID-19 vaccine. Shares in Moderna rose 2% in the extended session. The Biomedical Advanced Research and Development Authority within the Department of Health and Human Services awarded the cash to accelerate the company's development of the mRNA-1273 vaccine candidate and fund it through U.S. Food and Drug Administration licensure. Moderna said that it plans to begin a Phase 2 study in the second quarter of 2020 and start Phase 3 testing as soon as the fall of 2020. The company said it plans to hire 150 new staff this year in the U.S. "By investing now in our manufacturing process scale-up to enable large scale production for pandemic response, we believe that we would be able to supply millions of doses per month in 2020 and with further investments, tens of millions per month in 2021, if the vaccine candidate is successful in the clinic," Moderna Chief Executive Stéphane Bancel said in a statement. The first patient in the Phase 1 trial received a dose of the vaccine candidate March 16.

    New Data on Moderna’s Zika Vaccine Could Raise Hopes for Covid-19 Vaccine

    Biotech company’s CEO says the positive experience with experimental vaccines so far makes him more confident that the Covid-19 vaccine will work.

    Read full story

    These 21 companies are working on coronavirus treatments or vaccines — here’s where things stand

    Read full story

    There’s scant evidence so far for chloroquine as a COVID-19 drug — but there’s already a shortage

    Coronavirus-Vaccine Hopes Have Lifted Moderna Stock. Planned Sales by Insiders Have Surged.

    The biotech’s shares are on the rise, and so are automated sales of Moderna shares through plans set up by company insiders.

    Read full story

    Charting a consolidation phase, S&P 500 thus far maintains major support

    ProPublica Chairman Paul Sagan Bought Moderna Stock Before Latest Surge

    Sagan is the first and only insider at the biotech to buy shares. He bought shares in Moderna’s secondary offering in February.

    JNJ’s Covid-19 Vaccine Could Be Ready Early Next Year

    The company said it could have a Covid-19 vaccine available for emergency use early next year and it would begin manufacturing the vaccine immediately.

    Here Are 9 of The Most Important Efforts To Make a Coronavirus Vaccine

    There are currently at least 47 Covid-19 vaccine programs under way. Here are some to keep an eye on.

    Race for Coronavirus Vaccine Accelerates as Pfizer Says U.S. Testing to Begin Next Week

    The push for a vaccine to combat the new coronavirus is moving faster than researchers and drugmakers expected, with Pfizer joining several other groups saying that they had accelerated the timetable for testing and that a vaccine could be ready for emergency use in the fall.

    on The Wall Street Journal

    What to Know About the New Coronavirus

    Concern is high about the deadly virus behind a fast-growing global outbreak. Here is what health officials know so far.

    on The Wall Street Journal

    What We Know About Coronavirus Tests, Treatment and Vaccines

    After the Food and Drug Administration opened the door for authorized companies and labs to do virus testing, dozens of options are emerging. We are updating this guide regularly with what we learn about the state of testing and treatment across the U.S.

    on The Wall Street Journal

    Drugmakers Prepare to Make Coronavirus Treatments

    Drugmakers are reconfiguring manufacturing plants and hiring hundreds of new workers to be ready to make coronavirus drugs and vaccines should they prove in testing to be effective in fighting off the virus.

    on The Wall Street Journal

    U.S. Stocks Drop Along With Oil Prices

    U.S. stocks slid to start another potentially volatile week as investors continued to try to gauge the extent of the economic damage from the coronavirus pandemic.

    on The Wall Street Journal

    ESG Insights - Big Pharma Teams Up to Find Coronavirus Treatments

    The Wall Street Journal’s ESG research analysts saw positive implications for GlaxoSmithKline, Sanofi, SoftBank, BYD, Apple, Google, Tesla and Shell.

    on The Wall Street Journal

    Moderna Gets U.S. Funding for Experimental Coronavirus Vaccine

    The Cambridge, Mass., company also said it plans to hire up to 150 new employees to scale up manufacturing of doses for the studies, and to develop processes for large-scale manufacturing if the studies succeed.

    on The Wall Street Journal

    Shoes to Masks: Corporate Innovation Flourishes in Coronavirus Fight

    From face shields to vaccines, ingenuity is emerging from surprising corners of the private sector. It is a 21st-century version of FDR’s “Arsenal of Democracy.”

    on The Wall Street Journal

    American Companies Innovate to Fight the Coronavirus, in Echo of World War II

    From face shields to vaccines, ingenuity is emerging from surprising corners of the private sector. It is a 21st century version of FDR’s ‘Arsenal of Democracy.’

    on The Wall Street Journal

    GlaxoSmithKline, Sanofi Team Up for Coronavirus Vaccine

    GlaxoSmithKline, the world’s biggest vaccine maker, and Sanofi, the fourth largest, are joining forces to develop a coronavirus vaccine that, if successful, could pump out hundreds of millions of doses by the second half of 2021.

    on The Wall Street Journal

    Pfizer Identifies Lead Coronavirus Drug Candidate

    The drugmaker has found a promising but early potential coronavirus treatment, which the company aims to begin testing in patients this summer.

    on The Wall Street Journal

    Scientists Rush to Find Coronavirus Cure—but It Still Isn’t Fast Enough

    Scientists are mobilizing at record speed to develop a vaccine and effective treatments. The pandemic is moving even faster.

    on The Wall Street Journal

    Inside the Race to Find a Coronavirus Cure

    Scientists are mobilizing at record speed to develop a vaccine and effective treatments. The pandemic is moving even faster.

    on The Wall Street Journal

    Big Tobacco Joins Race for Coronavirus Vaccine

    British American Tobacco is developing a potential vaccine grown in tobacco plants, while Medicago, a biotech firm partly owned by Philip Morris International, is pursuing a similar effort.

    on The Wall Street Journal

    Who Has Covid-19? What We Know About Coronavirus Tests, Treatment

    After the Food and Drug Administration opened the door for authorized companies and labs, dozens of options are emerging. We are updating this guide regularly with what we learn about the state of testing and treatment across the U.S.

    on The Wall Street Journal

    Sanofi CEO: ‘The One-Meeting Trip Will Disappear’

    Chief Executive Paul Hudson and many of the French drugmaker’s 100,000 employees are navigating new ways of working as the company tries to find a vaccine or treatment to overcome the coronavirus pandemic.

    on The Wall Street Journal

    Investors Are All Amateur Epidemiologists Now

    There are two ways to invest in this environment: One is to listen to the epidemiologists; the other is to look for a margin of safety.

    on The Wall Street Journal

    A Vaccine Wildcard From Big Tobacco

    British American Tobacco is the most unlikely contender yet in the race to find a vaccine against the new coronavirus.

    on The Wall Street Journal

    Johnson & Johnson to Begin Human Trials of Covid-19 Vaccine by September

    Johnson & Johnson said that it had made progress on a vaccine to prevent Covid-19 and that the product could be ready in early 2021.

    on The Wall Street Journal

    A Onetime Germ-Warfare Site Is Army’s Front Line in Coronavirus Battle

    The Army is manufacturing strains of the coronavirus at a former biowarfare site in Maryland as it gears up to test a slate of potential vaccines.

    on The Wall Street Journal

    Recent News

    • Other News
    • Press Releases

    Race for Coronavirus Vaccine Accelerates as Pfizer Says U.S. Testing to Begin Next Week

    The push for a vaccine to combat the new coronavirus is moving faster than researchers and drugmakers expected, with Pfizer joining several other groups saying that they had accelerated the timetable for testing and that a vaccine could be ready for emergency use in the fall.

    on The Wall Street Journal

    Moderna (MRNA) Stock Moves -0.35%: What You Should Know

    Moderna (MRNA) closed the most recent trading day at $47.88, moving -0.35% from the previous trading session.

    on Zacks.com

    Moderna Stock Is Still Worth a Buy While It’s in Breakout Mode

    Moderna Stock Is Still Worth a Buy While It’s in Breakout Mode

    on InvestorPlace.com

    Pfizer to make "hundreds of millions" doses of COVID-19 vaccine next year - CEO

    Pfizer to make "hundreds of millions" doses of COVID-19 vaccine next year - CEO

    on Seeking Alpha

    Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader

    Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader

    on Seeking Alpha

    3 Stocks to Benefit From Race to Develop Coronavirus Vaccines

    Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.

    on Zacks.com

    9 Healthcare Stocks to Buy Even After the Coronavirus Fades

    9 Healthcare Stocks to Buy Even After the Coronavirus Fades

    on InvestorPlace.com

    What to Know About the New Coronavirus

    Concern is high about the deadly virus behind a fast-growing global outbreak. Here is what health officials know so far.

    on The Wall Street Journal

    What We Know About Coronavirus Tests, Treatment and Vaccines

    After the Food and Drug Administration opened the door for authorized companies and labs to do virus testing, dozens of options are emerging. We are updating this guide regularly with what we learn about the state of testing and treatment across the U.S.

    on The Wall Street Journal

    Wall Street Breakfast: Earnings Season Kicks Into High Gear

    Wall Street Breakfast: Earnings Season Kicks Into High Gear

    on Seeking Alpha

    Coronavirus vaccine could be ready in 2020

    Coronavirus vaccine could be ready in 2020

    on Seeking Alpha

    Moderna submits IND application for Phase 2 COVID-19 study

    Moderna submits IND application for Phase 2 COVID-19 study

    on Seeking Alpha

    Moderna Scores Huge Grant, Leads Charge Toward Coronavirus Vaccine

    Moderna Scores Huge Grant, Leads Charge Toward Coronavirus Vaccine

    on InvestorPlace.com

    Stocks To Watch: Tech Powerhouses Lead Earnings Blitz

    Stocks To Watch: Tech Powerhouses Lead Earnings Blitz

    on Seeking Alpha

    Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

    Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

    on Zacks.com

    Biotech Melt-Up

    Biotech Melt-Up

    on Seeking Alpha

    Drugmakers Prepare to Make Coronavirus Treatments

    Drugmakers are reconfiguring manufacturing plants and hiring hundreds of new workers to be ready to make coronavirus drugs and vaccines should they prove in testing to be effective in fighting off the virus.

    on The Wall Street Journal

    Moderna Faces Tough Threats in the Short and Long Term

    Moderna Faces Tough Threats in the Short and Long Term

    on InvestorPlace.com

    Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

    Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

    on Zacks.com

    Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

    The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

    on Zacks.com

    Stocks Enjoying Strong Market Performance Despite Economic And Industry Slowdown- ZM, MRNA, NVDA

    Stocks Enjoying Strong Market Performance Despite Economic And Industry Slowdown- ZM, MRNA, NVDA

    on The Market Signal

    Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow?

    Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow?

    on PR Newswire - PRF

    Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

    Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

    on BusinessWire - BZX

    Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020

    Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020

    on BusinessWire - BZX

    Scientists Gaining Hope for Finding COVID-19 Vaccine Faster Than Expected

    Scientists Gaining Hope for Finding COVID-19 Vaccine Faster Than Expected

    on Financial News Media

    Scientists Gaining Hope for Finding COVID-19 Vaccine Faster Than Expected

    Scientists Gaining Hope for Finding COVID-19 Vaccine Faster Than Expected

    on PR Newswire - PRF

    Thinking about trading options or stock in Beyond Meat, Walt Disney, Lockheed Martin, Moderna, or Tesla?

    Thinking about trading options or stock in Beyond Meat, Walt Disney, Lockheed Martin, Moderna, or Tesla?

    on PR Newswire - PRF

    Clinical Trials for COVID-19 Treatments or Vaccines Reaching Unprecedented Levels

    Clinical Trials for COVID-19 Treatments or Vaccines Reaching Unprecedented Levels

    on Financial News Media

    Clinical Trials for COVID-19 Treatments or Vaccines Reaching Unprecedented Levels

    Clinical Trials for COVID-19 Treatments or Vaccines Reaching Unprecedented Levels

    on PR Newswire - PRF

    Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

    Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

    on BusinessWire - BZX

    MRNA Cancer Vaccines and Therapeutics Market to See Major Growth by 2025

    MRNA Cancer Vaccines and Therapeutics Market to See Major Growth by 2025

    on HTF Market Intelligence

    Companies Rush to Develop Innovative Viral Medicines

    Companies Rush to Develop Innovative Viral Medicines

    on PR Newswire - PRF

    Thinking about buying stock in Aytu Bioscience, Boeing, Canopy Growth Corp, Moderna, or Rite Aid?

    Thinking about buying stock in Aytu Bioscience, Boeing, Canopy Growth Corp, Moderna, or Rite Aid?

    on PR Newswire - PRF

    Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response

    Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response

    on PR Newswire - PRF

    Growing Number of Coronavirus Vaccines Under Development With 3 in Human Trials

    Growing Number of Coronavirus Vaccines Under Development With 3 in Human Trials

    on Financial News Media

    Growing Number of Coronavirus Vaccines Under Development With 3 in Human Trials

    Growing Number of Coronavirus Vaccines Under Development With 3 in Human Trials

    on PR Newswire - PRF

    Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day

    Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day

    on BusinessWire - BZX

    Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

    Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

    on BusinessWire - BZX

    Cancer Vaccines Market To Expand As Number Of Cancer Cases Arising Due To Infections Increase During 2020 – 2028

    Cancer Vaccines Market To Expand As Number Of Cancer Cases Arising Due To Infections Increase During 2020 – 2028

    on AmericaNewsHour

    Moderna to Present at 19th Annual Needham Healthcare Conference

    Moderna to Present at 19th Annual Needham Healthcare Conference

    on BusinessWire - BZX

    Moderna Inc.

    Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. (See Full Profile)

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 10 Full Ratings
    欧美成AⅤ人片在线观看